Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

36 37 Next >

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Near Top of Volume Charts in Tuesday Trading

October 31, 2023

Via Investor Brand Network

Why Are Stocks Down Today? ↗

October 31, 2023

Stocks are down today and investors wondering why have come to the right place as we have an answer to that question!

Via InvestorPlace

BB Stock Alert: What to Know as BlackBerry Announces CEO Departure ↗

October 31, 2023

BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week.

Via InvestorPlace

US Stocks Fall; Pfizer Swings To Q3 Loss ↗

October 31, 2023

U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17....

Via Benzinga

Topics Stocks

Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today? ↗

October 31, 2023

Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial.

Via InvestorPlace

5 Analysts Have This to Say About Sarepta Therapeutics ↗

September 26, 2023

Via Benzinga

Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2023

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 31, 2023

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...

Via Benzinga

Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 31, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

EMBARKNG On A New Label? New Sarepta DMD Data Leads To Old Debates ↗

October 30, 2023

Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older.

Via Talk Markets

Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy ↗

October 30, 2023

The drug didn't meet its primary goal in the pivotal study, but it met secondary measures.

Via Investor's Business Daily

Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy

October 30, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 27, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 25, 2023

Via Benzinga

Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results

October 25, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 24, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 19, 2023

Via Benzinga

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

October 10, 2023

Via Benzinga

Sarepta Therapeutics Stock Showing Rising Relative Strength ↗

October 09, 2023

Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

10 Health Care Stocks Whale Activity In Today's Session ↗

September 18, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 15, 2023

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 14, 2023

Via Benzinga

2 Top Growth Stocks to Buy With $500 ↗

September 14, 2023

No need to break the bank to invest in stocks.

Via The Motley Fool

Insiders Are Buying These 2 Stocks

September 08, 2023

Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment.

Via MarketBeat

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.